Effects of Acarbose on Polycystic Ovary Syndrome: A Meta-analysis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Experimental and clinical endocrinology & diabetes

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0034-1375676PMID 24941435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polycystic ovary syndrome

  2016cited by this paper
• Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome.

  2012cited by this paper
• Long‐term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome

  2011cited by this paper
• Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

  2010cited by this paper
• Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study

  2010cited by this paper
• Acarbose for Polycystic Ovary Syndrome

  2008cited by this paper
• Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.

  2008cited by this paper
• Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome.

  2007cited by this paper
• Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study.

  2005cited by this paper
• Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.

  2005cited by this paper
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

  2004cited by this paper
• [The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome].

  2003cited by this paper
• Metformin-associated lactic acidosis: case reports and literature review.

  2002cited by this paper
• Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance.

  2001cited by this paper
• [Metformin associated lactic acidosis--case reports and literature review].

  2000cited by this paper
• Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.

  1998cited by this paper
• Role of Hyperinsulinemia in the Pathogenesis of the Polycystic Ovary Syndrome, and Its Clinical Implications

  1997cited by this paper
• Acarbose reduces elevated testosterone serum concentrations in hyperinsulinaemic premenopausal women: a pilot study.

  1996cited by this paper
• The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

  1996cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Acarbose

  1996cited by this paper
• Detection of functional ovarian hyperandrogenism in women with androgen excess.

  1992cited by this paper
• [Diagnostic criteria for polycystic ovary syndrome].

  1989cited by this paper

• Synthesis, structural insights and bio-evaluation of N-phenoxyethylisatin hydrazones as potent α-glucosidase inhibitors

  2025cites this paper
• Gastrointestinal adverse effects of old and new antidiabetics: How do we deal with them in real life?

  2024cites this paper
• High levels of fatty acid-binding protein 5 excessively enhances fatty acid synthesis and proliferation of granulosa cells in polycystic ovary syndrome

  2024cites this paper
• Discovery of novel dihydro-pyrimidine hybrids: insight into the design, synthesis, biological evaluation and absorption, distribution, metabolism and excretion studies.

  2024cites this paper
• Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial.

  2024cites this paper
• Therapeutic potential of acarbose in ameliorating the metabolic and endocrinological complications of polycystic ovarian syndrome: a review

  2024influential citation
• Efectos adversos gastrointestinales de viejos y nuevos antidiabéticos: ¿cómo los enfrentamos en la vida real?

  2024cites this paper
• The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials

  2023cites this paper
• Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome

  2023cites this paper
• High-Fiber Diet or Combined With Acarbose Alleviates Heterogeneous Phenotypes of Polycystic Ovary Syndrome by Regulating Gut Microbiota

  2022cites this paper
• Current and emerging drug treatment strategies for polycystic ovary syndrome

  2022influential citation
• Troxerutin attenuates insulin resistance via pancreatic IL-22/JAK1/STAT3 signaling activation in dihydrotestosterone-induced PCOS rats.

  2022cites this paper
• Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis

  2021cites this paper
• Efficacy of Salvia officinalis extract on the prevention of insulin resistance in euglycemic patients with polycystic ovary syndrome: A double-blinded placebo-controlled clinical trial.

  2020cites this paper
• Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS

  2020cites this paper
• Intervention of Prediabetes by Flavonoids From Oroxylum indicum

  2019cites this paper
• Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility

  2019cites this paper
• Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews

  2019cites this paper
• Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics.

  2019cites this paper
• Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews

  2018cites this paper
• Pediatric obesity: Current concepts.

  2018cites this paper
• Pregnancy-related outcomes for women with polycystic ovary syndrome

  2017cites this paper
• Combination of flavonoids from Oroxylum indicum seed extracts and acarbose improves the inhibition of postprandial blood glucose: In vivo and in vitro study.

  2017cites this paper
• Comparing the Effect of Metformin and Acarbose Accompanying Clomiphene on the Successful Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome

  2016cites this paper